Detection of circulating tumor cells from lung cancer patients in the era of targeted therapy: Promises, drawbacks and pitfalls

Current Molecular Medicine

Volumn 14, Issue 4, 2014, Pages 440-456

  Hofman, V ^a,b,c   Ilie, M ^a,b,c   Long, E ^a,b,c   Guibert, N ^b   Selva, E ^c   Washetine, K ^a,c   Mograbi, B ^b   Mouroux, J ^b,c   Venissac N ^c   Reverso Meinietti, J ^a   Milano, G ^d   Mazieres J ^e   Marquette, C H ^b,c   Paterlini Brechot P ^f   Hofman, P ^a,b,c,g  

^a PASTEUR HOSPITAL   (France)

^b UNIVERSITY OF NICE SOPHIA ANTIPOLIS   (France)

^c Pasteur Hospital   (France)

^d UNIVERSITÉ CÔTE D'AZUR   (France)

^e SERVICE DE PNEUMOLOGIE   (France)

^f INSERM   (France)

^g Equipe Labellisée Ligue Nationale contre le Cancer   (France)

Author keywords

Cancer screening; Circulating tumor cells; Diagnosis; Lung cancer; Personalized medicine; Prognosis; Targeted therapy

Indexed keywords

ARTICLE; CELL STRUCTURE; DISEASE COURSE; GENE MUTATION; HUMAN; IMMUNOFLUORESCENCE; LUNG CANCER; MOLECULARLY TARGETED THERAPY; POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL; LUNG NEOPLASMS; METABOLISM; METASTASIS; PATHOLOGY; PROGNOSIS; TUMOR EMBOLISM;

HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS;

EID: 84904038882     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/1566524014666140414205455     Document Type: Article

References (145)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
2. Mazzone P, Mekhail T. Current and emerging medical treatments for non-small cell lung cancer: a primer for pulmonologists. Respir Med 2012; 106: 473-92.
3. Cagle PT, Allen TC. Lung cancer genotype-based therapy and predictive biomarkers: present and future. Arch Pathol Lab Med 2012; 136: 1482-91.
4. Cheng L, Alexander RE, Maclennan GT, et al. Molecular pathology of lung cancer: key to personalized medicine. Mod Pathol 2012; 25: 347-69.
5. Oktay MH, Hui P. Molecular pathology as the driving force for personalized oncology. Expert Rev Mol Diagn 2012; 12: 811-3.
6. Wender R, Fontham ET, Barrera E, Jr., et al. American Cancer Society lung cancer screening guidelines. CA Cancer J Clin 2013; 63: 107-17.
7. Bretthauer M, Kalager M. Principles, effectiveness and caveats in screening for cancer. Br J Surg 2013; 100: 55-65.
8. Quintans JS, Antoniolli AR, Onofre FM, Onofre AS. Detection of lung cancer using multiple genetic markers-a systematic review. Diagn Cytopathol 2013; 41: 834-42.
9. Madhavan D, Cuk K, Burwinkel B, Yang R. Cancer diagnosis and prognosis decoded by blood-based circulating microRNA signatures. Front Genet 2013; 4: 116.
10. Nana-Sinkam SP, Powell CA. Molecular biology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143: e30S-9S.
11. Nordgard O, Singh G, Solberg S, et al. Novel molecular tumor cell markers in regional lymph nodes and blood samples from patients undergoing surgery for non-small cell lung cancer. PLoS One 2013; 8: e62153.
12. Alix-Panabieres C, Pantel K. Circulating tumor cells: liquid biopsy of cancer. Clin Chem 2013; 59: 110-8.
13. Clarke LE, Leitzel K, Smith J, Ali SM, Lipton A. Epidermal growth factor receptor mRNA in peripheral blood of patients with pancreatic, lung, and colon carcinomas detected by RTPCR. Int J Oncol 2003; 22: 425-30.
14. Isobe K, Hata Y, Kobayashi K, et al. Clinical significance of circulating tumor cells and free DNA in non-small cell lung cancer. Anticancer Res 2012; 32: 3339-44.
15. Sanfiorenzo C, Ilie MI, Belaid A, et al. Two panels of plasma microRNAs as non-invasive biomarkers for prediction of recurrence in resectable NSCLC. PLoS One 2013; 8: e54596.
16. Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 2011; 11: 426-37.
17. Vlassov VV, Laktionov PP, Rykova EY. Circulating nucleic acids as a potential source for cancer biomarkers. Curr Mol Med 2010; 10: 142-65.
18. Hayes DF, Smerage JB. Circulating tumor cells. Prog Mol Biol Transl Sci 2010; 95: 95-112.
19. Paterlini-Brechot P, Benali NL. Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett 2007; 253: 180-204.
20. Paterlini-Brechot P. Organ-specific markers in circulating tumor cell screening: an early indicator of metastasis-capable malignancy. Future Oncol 2011; 7: 849-71.
21. Barriere G, Tartary M, Rigaud M. Epithelial mesenchymal transition: a new insight into the detection of circulating tumor cells. ISRN Oncol 2012; 2012: 382010.
22. Bonnomet A, Brysse A, Tachsidis A, et al. Epithelial-tomesenchymal transitions and circulating tumor cells. J Mammary Gland Biol Neoplasia 2010; 15: 261-73.
23. Hofman V, Ilie MI, Long E, et al. Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for non-small-cell lung carcinoma: comparison of the efficacy of the CellSearch Assay and the isolation by size of epithelial tumor cell method. Int J Cancer 2011; 129: 1651-60.
24. Hofman V, Long E, Ilie M, et al. Morphological analysis of circulating tumour cells in patients undergoing surgery for non-small cell lung carcinoma using the isolation by size of epithelial tumour cell (ISET) method. Cytopathology 2012; 23: 30-8.
25. Hofman VJ, Ilie MI, Bonnetaud C, et al. Cytopathologic detection of circulating tumor cells using the isolation by size of epithelial tumor cell method: promises and pitfalls. Am J Clin Pathol 2011; 135: 146-56.
26. Katz RL, He W, Khanna A, et al. Genetically abnormal circulating cells in lung cancer patients: an antigenindependent fluorescence in situ hybridization-based casecontrol study. Clin Cancer Res 2010; 16: 3976-87.
27. Hofman V, Bonnetaud C, Ilie MI, et al. Preoperative circulating tumor cell detection using the isolation by size of epithelial tumor cell method for patients with lung cancer is a new prognostic biomarker. Clin Cancer Res 2011; 17: 827-35.
28. Ge MJ, Shi D, Wu QC, Wang M, Li LB. Observation of circulating tumour cells in patients with non-small cell lung cancer by real-time fluorescent quantitative reverse transcriptase-polymerase chain reaction in peroperative period. J Cancer Res Clin Oncol 2006; 132: 248-56.
29. Kurusu Y, Yamashita J, Hayashi N, Mita S, Fujino N, Ogawa M. The sequence of vessel ligation affects tumor release into the circulation. J Thorac Cardiovasc Surg 1998; 116: 107-13.
30. Okumura Y, Tanaka F, Yoneda K, et al. Circulating tumor cells in pulmonary venous blood of primary lung cancer patients. Ann Thorac Surg 2009; 87: 1669-75.
31. Sawabata N, Okumura M, Utsumi T, et al. Circulating tumor cells in peripheral blood caused by surgical manipulation of non-small-cell lung cancer: pilot study using an immunocytology method. Gen Thorac Cardiovasc Surg 2007; 55: 189-92.
32. Fidler IJ. Metastasis: guantitative analysis of distribution and fate of tumor embolilabeled with 125 I-5-iodo-2'-deoxyuridine. J Natl Cancer Inst 1970; 45: 773-82.
33. Frisch SM, Screaton RA. Anoikis mechanisms. Curr Opin Cell Biol 2001; 13: 555-62.
34. Frisch SM, Schaller M, Cieply B. Mechanisms that link the oncogenic epithelial-mesenchymal transition to suppression of anoikis. J Cell Sci 2013; 126: 21-9.
35. Yu M, Bardia A, Wittner BS, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 2013; 339: 580-4.
36. Duda DG, Duyverman AM, Kohno M, et al. Malignant cells facilitate lung metastasis by bringing their own soil. Proc Natl Acad Sci U S A 2010; 107: 21677-82.
37. Friedl P, Gilmour D. Collective cell migration in morphogenesis, regeneration and cancer. Nat Rev Mol Cell Biol 2009; 10: 445-57.
38. Wu QD, Wang JH, Condron C, Bouchier-Hayes D, Redmond HP. Human neutrophils facilitate tumor cell transendothelial migration. Am J Physiol Cell Physiol 2001; 280: C814-22.
39. De Giorgi U, Mego M, Scarpi E, et al. Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer. Clin Breast Cancer 2012; 12: 264-9.
40. Kobayashi N, Usui S, Kikuchi S, et al. Preoperative lymphocyte count is an independent prognostic factor in node-negative non-small cell lung cancer. Lung Cancer 2012; 75: 223-7.
41. Zhang J, Huang SH, Li H, et al. Preoperative lymphocyte count is a favorable prognostic factor of disease-free survival in non-small-cell lung cancer. Med Oncol 2013; 30: 352.
42. Sarraf KM, Belcher E, Raevsky E, Nicholson AG, Goldstraw P, Lim E. Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J Thorac Cardiovasc Surg 2009; 137: 425-8.
43. Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelialmesenchymal-like transition and promotes metastasis. Cancer Cell 2011; 20: 576-90.
44. Varon D, Hayon Y, Dashevsky O, Shai E. Involvement of platelet derived microparticles in tumor metastasis and tissue regeneration. Thromb Res 2012; 130 (Suppl 1): S98-9.
45. Korpal M, Ell BJ, Buffa FM, et al. Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nat Med 2011; 17: 1101-8.
46. Fusi A, Liu Z, Kummerlen V, Nonnemacher A, Jeske J, Keilholz U. Expression of chemokine receptors on circulating tumor cells in patients with solid tumors. J Transl Med 2012; 10: 52.
47. Huh SJ, Liang S, Sharma A, Dong C, Robertson GP. Transiently entrapped circulating tumor cells interact with neutrophils to facilitate lung metastasis development. Cancer Res 2010; 70: 6071-82.
48. Comen E, Norton L, Massague J. Clinical implications of cancer self-seeding. Nat Rev Clin Oncol 2011; 8: 369-77.
49. Kim MY, Oskarsson T, Acharyya S, et al. Tumor self-seeding by circulating cancer cells. Cell 2009; 139: 1315-26.
50. Almog N. Molecular mechanisms underlying tumor dormancy. Cancer Lett 2010; 294: 139-46.
51. Uhr JW, Pantel K. Controversies in clinical cancer dormancy. Proc Natl Acad Sci U S A 2011; 108: 12396-400.
52. Sleeman JP, Nazarenko I, Thiele W. Do all roads lead to Rome? Routes to metastasis development. Int J Cancer 2011; 128: 2511-26.
53. Parkinson DR, Dracopoli N, Petty BG, et al. Considerations in the development of circulating tumor cell technology for clinical use. J Transl Med 2012; 10: 138.
54. Alix-Panabieres C, Schwarzenbach H, Pantel K. Circulating tumor cells and circulating tumor DNA. Annu Rev Med 2012; 63: 199-215.
55. Gorges TM, Tinhofer I, Drosch M, et al. Circulating tumour cells escape from EpCAM-based detection due to epithelialto-mesenchymal transition. BMC Cancer 2012; 12: 178.
56. Farace F, Massard C, Vimond N, et al. A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas. Br J Cancer 2011; 105: 847-53.
57. Lecharpentier A, Vielh P, Perez-Moreno P, Planchard D, Soria JC, Farace F. Detection of circulating tumour cells with a hybrid (epithelial/mesenchymal) phenotype in patients with metastatic non-small cell lung cancer. Br J Cancer 2011; 105: 1338-41.
58. Pantel K, Deneve E, Nocca D, et al. Circulating epithelial cells in patients with benign colon diseases. Clin Chem 2012; 58: 936-40.
59. Hou JM, Krebs M, Ward T, et al. Circulating tumor cells as a window on metastasis biology in lung cancer. Am J Pathol 2011; 178: 989-96.
60. Krebs MG, Hou JM, Sloane R, et al. Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and-independent approaches. J Thorac Oncol 2012; 7: 306-15.
61. Hayes DC, Secrist H, Bangur CS, et al. Multigene real-time PCR detection of circulating tumor cells in peripheral blood of lung cancer patients. Anticancer Res 2006; 26: 1567-75.
62. Kurusu Y, Yamashita J, Ogawa M. Detection of circulating tumor cells by reverse transcriptase-polymerase chain reaction in patients with resectable non-small-cell lung cancer. Surgery 1999; 126: 820-6.
63. Chen TF, Jiang GL, Fu XL, et al. CK19 mRNA expression measured by reverse-transcription polymerase chain reaction (RT-PCR) in the peripheral blood of patients with non-small cell lung cancer treated by chemo-radiation: an independent prognostic factor. Lung Cancer 2007; 56: 105-14.
64. Guo Y, Wang J, Huang P. Clinical Significance of CK20, CK19, CEA mRNAs in Peripheral Blood from Lung Cancer Patients. Zhongguo Fei Ai Za Zhi 2009; 12: 1013-7.
65. Huang TH, Wang Z, Li Q, Li FR, Qi H, Zhou HX. Clinical significance of enrichment and detection of circulating tumor cells in NSCLC patients with immunomagnetic beads. Zhonghua Zhong Liu Za Zhi 2007; 29: 676-80.
66. Novaes M, Bendit I, Garicochea B, del Giglio A. Reverse transcriptase-polymerase chain reaction analysis of cytokeratin 19 expression in the peripheral blood mononuclear cells of normal female blood donors. Mol Pathol 1997; 50: 209-11.
67. Peck K, Sher YP, Shih JY, Roffler SR, Wu CW, Yang PC. Detection and quantitation of circulating cancer cells in the peripheral blood of lung cancer patients. Cancer Res 1998; 58: 2761-5.
68. Kowalewska M, Chechlinska M, Markowicz S, Kober P, Nowak R. The relevance of RT-PCR detection of disseminated tumour cells is hampered by the expression of markers regarded as tumour-specific in activated lymphocytes. Eur J Cancer 2006; 42: 2671-4.
69. Zieglschmid V, Hollmann C, Bocher O. Detection of disseminated tumor cells in peripheral blood. Crit Rev Clin Lab Sci 2005; 42: 155-96.
70. Devriese LA, Bosma AJ, van de Heuvel MM, Heemsbergen W, Voest EE, Schellens JH. Circulating tumor cell detection in advanced non-small cell lung cancer patients by multimarker QPCR analysis. Lung Cancer 2012; 75: 242-7.
71. Schuster R, Max N, Mann B, et al. Quantitative real-time RTPCR for detection of disseminated tumor cells in peripheral blood of patients with colorectal cancer using different mRNA markers. Int J Cancer 2004; 108: 219-27.
72. Vona G, Sabile A, Louha M, et al. Isolation by size of epithelial tumor cells: a new method for the immunomorphological and molecular characterization of circulating tumor cells. Am J Pathol 2000; 156: 57-63.
73. Hofman V, Ilie M, Long-Mira E, et al. Usefulness of Immunocytochemistry for the Detection of the BRAF(V600E) Mutation in Circulating Tumor Cells from Metastatic Melanoma Patients. J Invest Dermatol 2013; 133: 1378-81.
74. Ilie M, Long E, Butori C, et al. ALK-gene rearrangement, a comparative analysis on circulating tumour cells and tumour tissue from lung adenocarcinoma patients. Ann Oncol 2012; 23: 2907-13.
75. Krivacic RT, Ladanyi A, Curry DN, et al. A rare-cell detector for cancer. Proc Natl Acad Sci U S A 2004; 101: 10501-4.
76. Hsieh HB, Marrinucci D, Bethel K, et al. High speed detection of circulating tumor cells. Biosens Bioelectron 2006; 21: 1893-9.
77. Marrinucci D, Bethel K, Bruce RH, et al. Case study of the morphologic variation of circulating tumor cells. Hum Pathol 2007; 38: 514-9.
78. Hosokawa M, Yoshikawa T, Negishi R, et al. Microcavity array system for size-based enrichment of circulating tumor cells from the blood of patients with small-cell lung cancer. Anal Chem 2013; 85: 5692-8.
79. Alix-Panabieres C. EPISPOT assay: detection of viable DTCs/CTCs in solid tumor patients. Recent Results Cancer Res 2012; 195: 69-76.
80. Christoph DC, Hoffmann AC, Gauler TC, et al. Detection of circulating lung cancer cells with strong thymidylate synthase reactivity in the peripheral blood of a patient with pulmonary adenocarcinoma treated with pemetrexed. J Thorac Oncol 2012; 7: 766-7.
81. Desitter I, Guerrouahen BS, Benali-Furet N, et al. A new device for rapid isolation by size and characterization of rare circulating tumor cells. Anticancer Res 2011; 31: 427-41.
82. Dong Y, Skelley AM, Merdek KD, et al. Microfluidics and circulating tumor cells. J Mol Diagn 2013; 15: 149-57.
83. Galanzha EI, Shashkov EV, Kelly T, Kim JW, Yang L, Zharov VP. In vivo magnetic enrichment and multiplex photoacoustic detection of circulating tumour cells. Nat Nanotechnol 2009; 4: 855-60.
84. Gauthier LR, Granotier C, Soria JC, et al. Detection of circulating carcinoma cells by telomerase activity. Br J Cancer 2001; 84: 631-5.
85. Gerges N, Rak J, Jabado N. New technologies for the detection of circulating tumour cells. Br Med Bull 2010; 94: 49-64.
86. Hou HW, Warkiani ME, Khoo BL, et al. Isolation and retrieval of circulating tumor cells using centrifugal forces. Sci Rep 2013; 3: 1259.
87. Huang SB, Wu MH, Lin YH, et al. High-purity and label-free isolation of circulating tumor cells (CTCs) in a microfluidic platform by using optically-induced-dielectrophoretic (ODEP) force. Lab Chip 2013; 13: 1371-83.
88. Kim SJ, Masago A, Tamaki Y, et al. A novel approach using telomerase-specific replication-selective adenovirus for detection of circulating tumor cells in breast cancer patients. Breast Cancer Res Treat 2011; 128: 765-73.
89. Mordant P, Loriot Y, Lahon B, et al. Bioluminescent orthotopic mouse models of human localized non-small cell lung cancer: feasibility and identification of circulating tumour cells. PLoS One 2011; 6: e26073.
90. Nagrath S, Sequist LV, Maheswaran S, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007; 450: 1235-9.
91. Neugebauer U, Bocklitz T, Clement JH, Krafft C, Popp J. Towards detection and identification of circulating tumour cells using Raman spectroscopy. Analyst 2010; 135: 3178-82.
92. Nieva J, Wendel M, Luttgen MS, et al. High-definition imaging of circulating tumor cells and associated cellular events in non-small cell lung cancer patients: a longitudinal analysis. Phys Biol 2012; 9: 016004.
93. Rolle A, Gunzel R, Pachmann U, Willen B, Hoffken K, Pachmann K. Increase in number of circulating disseminated epithelial cells after surgery for non-small cell lung cancer monitored by MAINTRAC(R) is a predictor for relapse: A preliminary report. World J Surg Oncol 2005; 3: 18.
94. Sheu CC, Yu YP, Tsai JR, et al. Development of a membrane array-based multimarker assay for detection of circulating cancer cells in patients with non-small cell lung cancer. Int J Cancer 2006; 119: 1419-26.
95. Stott SL, Hsu CH, Tsukrov DI, et al. Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci U S A 2010; 107: 18392-7.
96. Talasaz AH, Powell AA, Huber DE, et al. Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device. Proc Natl Acad Sci U S A 2009; 106: 3970-5.
97. Wang Y, Zhang Y, Du Z, Wu M, Zhang G. Detection of micrometastases in lung cancer with magnetic nanoparticles and quantum dots. Int J Nanomedicine 2012; 7: 2315-24.
98. Wu CH, Lin SR, Yu FJ, et al. Development of a highthroughput membrane-array method for molecular diagnosis of circulating tumor cells in patients with gastric cancers. Int J Cancer 2006; 119: 373-9.
99. Tanaka F, Yoneda K, Kondo N, et al. Circulating tumor cell as a diagnostic marker in primary lung cancer. Clin Cancer Res 2009; 15: 6980-6.
100. Hirose T, Murata Y, Oki Y, et al. Relationship of circulating tumor cells to the effectiveness of cytotoxic chemotherapy in patients with metastatic non-small-cell lung cancer. Oncol Res 2012; 20: 131-7.
101. Krebs MG, Sloane R, Priest L, et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol 2011; 29: 1556-63.
102. Funaki S, Sawabata N, Nakagiri T, et al. Novel approach for detection of isolated tumor cells in pulmonary vein using negative selection method: morphological classification and clinical implications. Eur J Cardiothorac Surg 2011; 40: 322-7.
103. Hou JM, Krebs MG, Lancashire L, et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol 2012; 30: 525-32.
104. Sher YP, Shih JY, Yang PC, et al. Prognosis of non-small cell lung cancer patients by detecting circulating cancer cells in the peripheral blood with multiple marker genes. Clin Cancer Res 2005; 11: 173-9.
105. Sienel W, Seen-Hibler R, Mutschler W, Pantel K, Passlick B. Tumour cells in the tumour draining vein of patients with nonsmall cell lung cancer: detection rate and clinical significance. Eur J Cardiothorac Surg 2003; 23: 451-6.
106. Wu C, Hao H, Li L, et al. Preliminary investigation of the clinical significance of detecting circulating tumor cells enriched from lung cancer patients. J Thorac Oncol 2009; 4: 30-6.
107. Yamashita J, Matsuo A, Kurusu Y, Saishoji T, Hayashi N, Ogawa M. Preoperative evidence of circulating tumor cells by means of reverse transcriptase-polymerase chain reaction for carcinoembryonic antigen messenger RNA is an independent predictor of survival in non-small cell lung cancer: a prospective study. J Thorac Cardiovasc Surg 2002; 124: 299-305.
108. Yie SM, Lou B, Ye SR, et al. Clinical significance of detecting survivin-expressing circulating cancer cells in patients with non-small cell lung cancer. Lung Cancer 2009; 63: 284-90.
109. Yoon SO, Kim YT, Jung KC, Jeon YK, Kim BH, Kim CW. TTF-1 mRNA-positive circulating tumor cells in the peripheral blood predict poor prognosis in surgically resected non-small cell lung cancer patients. Lung Cancer 2011; 71: 209-16.
110. Hiltermann TJ, Pore MM, van den Berg A, et al. Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor. Ann Oncol 2012; 23: 2937-42.
111. Hou JM, Greystoke A, Lancashire L, et al. Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy. Am J Pathol 2009; 175: 808-16.
112. Khan MS, Kirkwood A, Tsigani T, et al. Circulating tumor cells as prognostic markers in neuroendocrine tumors. J Clin Oncol 2013; 31: 365-72.
113. Naito T, Tanaka F, Ono A, et al. Prognostic impact of circulating tumor cells in patients with small cell lung cancer. J Thorac Oncol 2012; 7: 512-9.
114. Liu Y, Liu B, Li XY, et al. A comparison of ARMS and direct sequencing for EGFR mutation analysis and tyrosine kinase inhibitors treatment prediction in body fluid samples of nonsmall-cell lung cancer patients. J Exp Clin Cancer Res 2011; 30: 111.
115. Maheswaran S, Sequist LV, Nagrath S, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008; 359: 366-77.
116. Punnoose EA, Atwal S, Liu W, et al. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. Clin Cancer Res 2012; 18: 2391-401.
117. Pailler E, Adam J, Barthelemy A, et al. Detection of Circulating Tumor Cells Harboring a Unique ALK Rearrangement in ALK-Positive Non-Small-Cell Lung Cancer. J Clin Oncol 2013; 31: 2273-81.
118. Bergethon K, Shaw AT, Ou SH, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012; 30: 863-70.
119. Dutt A, Ramos AH, Hammerman PS, et al. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One 2011; 6: e20351.
120. Ilie M, Long E, Hofman V, et al. Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients. Ann Oncol 2013; 24: 742-8.
121. Rekhtman N, Paik PK, Arcila ME, et al. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res 2012; 18: 1167-76.
122. Weiss J, Sos ML, Seidel D, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2010; 2: 62ra93.
123. Das M, Riess JW, Frankel P, et al. ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy. Lung Cancer 2012; 77: 421-6.
124. Hofman P, Ilie M, Hofman V, et al. Immunohistochemistry to identify EGFR mutations or ALK rearrangements in patients with lung adenocarcinoma. Ann Oncol 2012; 23: 1738-43.
125. Ilie MI, Hofman V, Bonnetaud C, et al. Usefulness of tissue microarrays for assessment of protein expression, gene copy number and mutational status of EGFR in lung adenocarcinoma. Virchows Arch 2010; 457: 483-95.
126. Ilie M, Hofman P. Pitfalls in lung cancer molecular pathology: how to limit them in routine practice? Curr Med Chem 2012; 19: 2638-51.
127. Cassatella MC, Zorzino L, Sandri MT. Single circulating tumor cell profiling: a new perspective for targeted therapy? Future Oncol 2012; 8: 1253-6.
128. Allan AL, Keeney M. Circulating tumor cell analysis: technical and statistical considerations for application to the clinic. J Oncol 2010; 2010: 426218.
129. Balic M, Williams A, Lin H, Datar R, Cote RJ. Circulating tumor cells: from bench to bedside. Annu Rev Med 2013; 64: 31-44.
130. Coumans FA, Ligthart ST, Uhr JW, Terstappen LW. Challenges in the enumeration and phenotyping of CTC. Clin Cancer Res 2012; 18: 5711-8.
131. Gorges TM, Pantel K. Circulating tumor cells as therapyrelated biomarkers in cancer patients. Cancer Immunol Immunother 2013; 62: 931-9.
132. Joosse SA, Pantel K. Biologic challenges in the detection of circulating tumor cells. Cancer Res 2013; 73: 8-11.
133. Lianidou ES. Circulating tumor cells--new challenges ahead. Clin Chem 2012; 58: 805-7.
134. O'Flaherty JD, Gray S, Richard D, et al. Circulating tumour cells, their role in metastasis and their clinical utility in lung cancer. Lung Cancer 2012; 76: 19-25.
135. Pantel K, Alix-Panabieres C. Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol Med 2010; 16: 398-406.
136. Wendel M, Bazhenova L, Boshuizen R, et al. Fluid biopsy for circulating tumor cell identification in patients with early-and late-stage non-small cell lung cancer: a glimpse into lung cancer biology. Phys Biol 2012; 9: 016005.
137. Kaiser J. Medicine. Cancer's circulation problem. Science 2010; 327: 1072-4.
138. Stovold R, Blackhall F, Meredith S, Hou J, Dive C, White A. Biomarkers for small cell lung cancer: neuroendocrine, epithelial and circulating tumour cells. Lung Cancer 2012; 76: 263-8.
139. Gervasoni A, Monasterio Munoz RM, Wengler GS, Rizzi A, Zaniboni A, Parolini O. Molecular signature detection of circulating tumor cells using a panel of selected genes. Cancer Lett 2008; 263: 267-79.
140. Punnoose EA, Atwal SK, Spoerke JM, et al. Molecular biomarker analyses using circulating tumor cells. PLoS One 2010; 5: e12517.
141. Smirnov DA, Zweitzig DR, Foulk BW, et al. Global gene expression profiling of circulating tumor cells. Cancer Res 2005; 65: 4993-7.
142. Wicha MS, Hayes DF. Circulating tumor cells: not all detected cells are bad and not all bad cells are detected. J Clin Oncol 2011; 29: 1508-11.
143. Long E, Hofman V, Ilie M, et al. Setting up a department of molecular pathology in oncology in a pathology laboratory (LPCE, CHU de Nice). Ann Pathol 2013; 33: 24-37.
144. Liu L, Liao GQ, He P, et al. Detection of circulating cancer cells in lung cancer patients with a panel of marker genes. Biochem Biophys Res Commun 2008; 372: 756-60.
145. Taniguchi K, Uchida J, Nishino K, et al. Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas. Clin Cancer Res 2011; 17: 7808-15.